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Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality globally. 
The most cost-effective imaging strategy to diagnose CAD in patients with stable chest pain is 
however uncertain.  
Objective: To review the evidence on comparative cost-effectiveness of different imaging strategies 
for patients presenting with stable chest pain symptoms suggestive for CAD.   
Design: Systematic review. 
Study selection: Studies performing a formal economic evaluation or decision analysis in the English 
language published between January 1995 and December 2015 were identified using PubMed, 
Medline (OvidSP), Embase, Web of Science, Cochrane economic evaluations library and EconLit. 
Reviews and meta-analyses were excluded. Two independent reviewers assessed titles and abstracts. 
Of the 4498 titles identified 70 met our selection criteria.  
Quality assessment: One reviewer used a modified version of the CHEERS checklist to assess study 
quality.  
Data extraction: One reviewer extracted data on study details, which were checked by a second 
reviewer. 
Results: There is a major heterogeneity between the available cost-effectiveness studies included in 
this study. The included studies compared very different testing strategies in very different ways and 
provided mostly short-term results. Strategies of no-testing and xECG were underrepresented. 
Nonetheless, the findings from this systematic review suggest that for patients with a low to 
intermediate prior probability of having obstructive CAD, CT coronary angiography (CTCA) may be 
cost-effective as an initial diagnostic imaging test in comparison with CAG or other non-invasive 
diagnostic tests. If functional testing is required, SE or SPECT are suggested to be cost-effective initial 
strategies in patients with intermediate prior probability of CAD. Yet, other functional testing 
strategies as xECG and PET scanning have not been studied as intensely. Immediate CAG is suggested 







to be a cost-effective strategy for patients at a high prior probability of having obstructive CAD whom 
may benefit from revascularisation.  
Conclusion.This study emphasises the inextricable link between clinical effectiveness and economic 
efficiency. Evidence suggests that the optimal diagnostic imaging strategy for individuals suspected of 
having CAD is CTCA for low and intermediate disease probability, followed by SE or SPECT as 
necessary, and invasive CAG for high disease probability. Further studies are needed to evaluate the 
cost-effectiveness of alternative non-invasive tests, including a no-testing strategy. 
Keywords: Coronary artery disease; stable chest pain; comparative cost-effectiveness; willingness-to-
pay threshold; non-invasive diagnostic imaging 
Abbreviations: 
CACS Coronary artery calcium scoring  
CAD Coronary artery disease 
CAG Catheter-based (invasive) coronary angiography 
CMRI   Cardiac magnetic resonance imaging 
CTCA CT coronary angiography 
ETT Exercise treadmill testing  
FFR  Fractional flow reserve 
MRI Magnetic resonance imaging 
MPI  Myocardial perfusion imaging  
MPS Myocardial perfusion spectroscopy 
PCI  Percutaneous coronary intervention 
PET  Positron emission tomography 
PTCA  Percutaneous transluminal coronary angioplasty  
QALY  Quality adjusted life year 
SE Stress echocardiography 







SPECT Single photon emission computed tomography 
xECG Stress electrocardiography 
 
Introduction 
Scope of the clinical problem 
Coronary artery disease (CAD) remains one of the leading causes of death globally among adult 
males and females alike (1). Stable chest pain symptoms (also referred to as stable angina) is an 
important manifestation of CAD. The lifetime risk of developing CAD depends on age, gender, 
ethnicity, geographic region and the presence of cardiovascular risk factors and is estimated to be 
38-51% in men and 12-33% in women (2). For patients who newly present with stable chest pain 
symptoms the evaluation of suspected CAD commonly includes a diagnostic workup to investigate 
for the presence of CAD. The evaluation should always begin with an appropriate history and physical 
examination. Catheter-based coronary angiography (CAG), at times combined with catheter-based 
fractional flow reserve (FFR) measurements, is the reference standard to diagnose functionally 
significant CAD. Since it is costly, invasive, and associated with a substantial risk of major adverse 
events, CAG is recommended as initial test for patients with a high prior probability of CAD (3). 
However, research has shown that only 41% of patients undergoing elective procedures of catheter 
based coronary angiographies are diagnosed with obstructive CAD (4). This stresses the need for 
better risk stratification, which is underlined by decision analyses showing that the optimal choice of 
further diagnostic investigation in patients with stable chest pain depends primarily on the prior 
probability of CAD (5-7). Deciding on subsequent diagnostic testing in patients with suspected CAD is 
however difficult, partly because of the many testing options currently available. 
Currently available non-invasive imaging tests 
Imaging tests play an important role in the diagnostic workup, and imaging results often determine 
prognosis and treatment. Stress electrocardiography (xECG) is a non-invasive diagnostic procedure 







that has been in widespread clinical use for decades to determine the presence of significant CAD.  
In clinical practice, cardiac imaging strategies are used when ECG abnormalities during xECG are 
nondiagnostic and when it is important to determine the extent and distribution of ischaemic 
myocardium. In addition, cardiac imaging strategies are used to exclude or confirm a positive or 
negative xECG as well as to decide whether a patient requires CAG (8).  
Owing to the rapid technological advancement in cardiovascular diagnostic imaging, many non-
invasive diagnostic tests are currently available which either evaluate coronary anatomy or the 
presence of inducible myocardial ischaemia (functional ischaemia testing), or both. CT coronary 
angiography (CTCA) evaluates coronary anatomy. Tests evaluating the presence of inducible 
myocardial ischaemia include stress echocardiography (SE), stress perfusion cardiac magnetic 
resonance imaging (CMRI), and myocardial perfusion imaging (MPI), i.e. myocardial perfusion 
scintigraphy (MPS) (either single-photon emission computed tomography [SPECT] or positron-
emission tomography [PET]). Furthermore, FFR can now be estimated from acquired computed 
tomography data (FFRct) based on computational fluid dynamics (9). Yet, although these tests are 
relatively non-invasive compared to catheter-based CAG, it should be noted that they still pose a 
burden to the individual patient, the health care system, and society at large, because they are 
associated with significant patient time, costs, radiation exposure and the risk of adverse events. 
Compounding the problem, physicians often request multiple tests in order to increase their 
confidence in the diagnosis and treatment plan of patients presenting with stable chest pain.  
Diagnostic imaging algorithms 
In order to minimise risks and burden to patients, radiation exposure and health care costs, 
diagnostic algorithms have been developed to optimise the diagnostic workup. These algorithms 
define a combination and sequence of tests, where the choice of each imaging test is determined by 
patient characteristics and the results of previously performed diagnostic tests. Imaging algorithms 
recommended by guidelines vary widely, demonstrating variability in clinical practice and attesting to 







the uncertainty about which algorithm is optimal (3, 10, 11). For example, the American College of 
Cardiology/American Heart Association and European Society of Cardiology recommend exercise 
electrocardiography to select patients for further diagnostic investigation, while the UK guidelines 
recommend using the computed tomography (CT) based coronary calcium score (CACS) in patients 
with a low to intermediate prior probability (10-29%) (11, 12). It has yet to be elucidated which 
imaging algorithm is optimal in terms of both costs and outcomes, i.e. is cost-effective.  
Purpose of this study 
In this paper we present a systematic review of available evidence on cost-effectiveness of currently 
available non-invasive imaging tests and imaging algorithms for the diagnostic workup of patients 
with stable chest pain symptoms who are suspected of having obstructive CAD.  
Materials and methods 
In a systematic literature search, we identified original articles that economically evaluated non-
invasive cardiac imaging strategies. We searched the electronic databases PubMed as publisher, 
Medline (OvidSP), Embase, Web of Science, Cochrane economic evaluations library and EconLit. The 
search included keywords corresponding to the index tests (CTCA, SE, MPS, PET, SPECT, CMRI, CACS, 
xECG, FFR), the reference test (CAG), the target condition CAD and cost-effectiveness. We used 
various synonyms including both text words and Medical Subject Headings (MeSH) terms to 
maximise the sensitivity of our search. 
We restricted our search to papers in English language published during the last 20 years (between 
January 1995 and December 2015) to identify economic evaluations studies and decision models 
with respect to non-invasive cardiac imaging tests. We only included papers dealing with adult 
patients presenting with chest pain symptoms suggesting the presence of stable CAD. Studies were 
excluded if the target condition was suspected acute coronary syndrome. We also excluded 
guidelines and studies focusing on detecting high risk (left main and triple vessel) CAD only, however, 
the references were checked for additional papers. 







We included studies if they met all of the following criteria: the study (1) performed a formal 
economic evaluation or decision analysis, (2) provided a thorough accounting of costs or evaluated 
both costs and effectiveness, (3) demonstrated total cost differences or reported either cost savings 
and increased effectiveness (= defined as dominance) or cost increases and gains in (quality adjusted) 
life year ([QA]LY) or healthy-year equivalents. Full-texts of articles containing the search terms in the 
title and/or abstract were selected by two reviewers independently (C.N.v.W. and M.Y.K.). Articles 
were excluded if both reviewers agreed they were ineligible. Discrepancies were resolved by 
consensus. Data of the included full texts on authors, reference, journal, year of publication, time 
horizon, perspective, country, imaging modalities compared, type of model, data sources, currency 
(type and year), threshold willingness-to-pay, reference case analysis, reference case result, 
suggested imaging strategy for low- intermediate prior probability of CAD, sensitivity analysis, 
influential input parameters, and generalisability were extracted by one reviewer (C.N.v.W.). 
Extracted data were checked for accuracy by a second reviewer (T.G.). Discrepancies were resolved 
by consensus. The quality of included studies was assessed by one reviewer (C.N.v.W.) using a 
modified version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
checklist (13) (see appendix table 4), as recommended by published guidelines (14, 15). 
Data synthesis 
Given the heterogeneity of the data, no formal quantitative pooling of results was performed. 
Synthesis of the data was performed qualitatively, and clinical implications are drawn. To enhance 
comparability, results were adjusted from the original papers by rounding the numbers and using a 
reporting format as recommended by reporting standards for cost-effectiveness analyses. Therefore, 
the data presented here may be different from the data reported in the original papers. Reported 
incremental cost-effectiveness ratios (ICERs) were recalculated from the reported data to ensure a 
correct comparison across the diagnostic imaging strategies.  








Comparative cost-effectiveness of non-invasive diagnostic imaging strategies 
Quality of included studies 
Our search resulted in 4498 titles of which 231 were identified as potentially eligible for inclusion 
based on title and/or abstract (see figure 1). Finally, 231 studies met our inclusion criteria. After161 
studies were excluded on the basis of our exclusion criteria, 70 were left for analysis. We present the 
results of our analysis in tables 1, 2, 3 and online appendix tables and figures. Quality of the studies 
was assessed according to a modified version of the CHEERS checklist and is presented in figure 2. 
The quality of the included cost-effectiveness studies was generally moderate to good. Most studies, 
however, did not provide details on price adjustments for inflation or currency conversion (item 11) 
and generalisability issues were poorly addressed. In addition, most studies provided details on 
currency type (item 10) used in the analyses, but some studies did not report the currency exchange 
year. 
Main findings 
There are some important differences between the included cost-effectiveness studies. A major issue 
is the heterogeneity of the studies included in this analysis. Many studies originate from different 
countries (see appendix figure 3), often take the perspective of the health care payer or health care 
provider (hospital), use a short term time horizon, or did not report the willingness-to-pay threshold 
(see appendix table 5 and 6). Therefore, the purpose was often to inform reimbursement or hospital 
services decisions, rather than decision making from a societal perspective as generally 
recommended in cost-effectiveness analyses (see appendix table 6 and appendix figures 4 & 5).  
There is also variation in the type of model used to perform an economic evaluation or decision 
analysis as well as the type of data sources used to inform these models. As can be seen from 
appendix table 7 and appendix figures 6 & 7, about one third of the studies (n=27/ 39%) used a 
decision tree combined with a long-term outcome modelling approach including Markov cohort 







simulation and state-transition microsimulation. In addition, some studies (n=13/ 19%) used a simple 
decision tree without modelling of long-term outcomes. 
Furthermore, a few studies (n=8/ 11%) used a Bayesian mathematical simulation model. The earlier 
mathematical simulation models, such as the one by Patterson et al 1995 (16), focused on diagnostic 
accuracy statistics as drivers for evaluating economic efficiency. In fact, these models were built on 
the principles of minimising costs through higher sensitivity and lower false-positive rates. Although 
these models rely on unrealistic assumptions, such as 100% of the patients with abnormal tests 
proceeding to CAG, they provide some insight into potentially cost-effective strategies and formed 
groundwork for several recent mathematical simulation models. The majority (n=35 / 50%) of studies 
however, used methods to look at costs only (n=17) or used miscellaneous methods to look both at 
costs and effectiveness (n=18). Some of these studies used costs per correct diagnosis as outcome 
(n=5) making them incomparable to cost/QALY cost-effectiveness studies.  
Looking at the willingness-to-pay (WTP) threshold, i.e. what society should be paying for a gain in 
effectiveness, many studies do not report a WTP threshold since they look only at costs or use short 
term outcomes. Few studies do report a WTP threshold (n=12/ 17%), however there is no 
international consensus on which WTP threshold to use and this threshold thus varies across 
countries, ranging from £10.000-€80.000/QALY. Additionally, we found considerable variability in the 
reporting of cost data (see appendix table 9) as well as in the quoted costs of different tests 
depending on assumptions about patient volumes and whether bottom-up costs or prices have been 
used. 
Furthermore, we found that about two-third of the included studies performed sensitivity analysis 
(see table 1). Of these, sensitivity analyses showed that the optimal diagnostic imaging strategy 
depends mostly on the prior probability of CAD, test characteristics and costs of a test. Only a few 
studies (n=10 / 14%) modelled all parameter uncertainty simultaneously (probabilities, utilities and 
costs) with probabilistic sensitivity analysis.  







There are also important differences in the reference case analyses performed and algorithms 
compared. In most studies the reference case analysis was not stratified by gender, although men 
and women may be quite different given their age and prior probability for CAD (see appendix table 
8). Arguably, only the study by Genders et al. 2015 (17), considered most but not all possible imaging 
tests. In fact, a wide range of imaging strategies was compared across the studies included in this 
systematic review. CTCA-based strategies are commonly compared, while only few studies 
comparing PET-based strategies (see table 2). In addition, only few studies considered a ‘no testing’ 
strategy (n=9/ 13%). Further, only few studies compared functional and anatomical tests (n=20/ 
29%). Most studies compared only functional tests (n=34/ 49%) and suppose SE to be superior over 
SPECT or CMRI. Furthermore, although potential cost savings are reported when SPECT-guided 
diagnostic strategies are compared with xECG-guided strategies, for example in a report by Marwick 
et al 2003 (18), it is not the case that SPECT is cost-effective when compared with other diagnostic 
imaging modalities (17). 
As can be seen from appendix table 5 and table 3, for most patients who present with typical or 
atypical angina, performing a non-invasive diagnostic test is a reasonable use of health care 
resources. Yet, as also can be seen from table 3, the cost-effectiveness of diagnostic strategies is 
strongly influenced by the prior probability of CAD. In 26 out of 32 studies considering CTCA, CTCA 
was cost-effective and suggested as a ‘gatekeeper’ (initial) test for adult patients with low-
intermediate prior probability of CAD (10%-≤50%) and prior to cardiac stress imaging. Yet, the prior 
probability thresholds for CAD below which CTCA is suggested and above which SE or SPECT varied 
across studies. CMRI and SE were preferred over xECG as initial stress test, and SE was cost-effective 
compared to SPECT in patients with a low-intermediate prior probability. Coronary angiography was 
cost-effective in patients with a high prior probability of CAD (≥70%). 
 








We present a systematic review of the published evidence on the comparative cost-effectiveness of 
currently available non-invasive imaging tests for the diagnostic workup of patients with stable chest 
pain symptoms who are suspected of having CAD. Our findings indicate that, in a setting of low to 
intermediate prior probability, there is no simple answer to what the optimal diagnostic imaging 
strategy is for individuals who are suspected of having CAD, as this depends on several variables: 
costs of the tests, test characteristics, prior probability, society’s willingness-to-pay threshold, 
optimisation criterion, availability of imaging tests, patient preference and local expertise. 
Differences across studies 
There are a number of differences across the included studies in our systematic review that should 
be recognised. Whereas the societal perspective is generally recommended in most countries, most 
studies took the perspective of the health care payer or health care provider (hospital). In addition, 
most studies used a short term time horizon for their analyses. Depending on the assumptions made, 
however, it is possible that long-term analyses produce results that are significantly different from 
those obtained with short-term analyses (19). For this reason, it is hard to draw any definitive 
conclusions from the data presented in this systematic review. In addition, in most of the included 
studies the diagnostic performance of non-invasive imaging tests is used in terms of ability to identify 
or exclude luminal stenosis, often compared with invasive CAG as reference standard. Yet, in clinical 
practice the primary aim of is rather to assess the origin of symptoms and the risk of acute (major) 
cardiac events, so that both hopefully can be minimised (20). Treatment strategies differed across 
studies with regards to revascularisation and optimal medical therapy. Yet, as has been shown in 
recent clinical trials, cardiac event rates with optimal medical therapy are quite low, even in patients 
with established CAD. The recent FAME 2 trial demonstrated no reduction in death or myocardial 
infarctions (MI) in patients with single or multi-vessel stable chest pain symptoms who underwent 
FFR-guided PCI of significant lesions, when added to OMT vs. OMT alone (21). Also in the COURAGE 







trial, a lack of clinical benefit for death or MI when PCI of angiographically significant lesions was 
added to OMT in stable CAD patients was shown (22). This supports the concept that the incremental 
use of preventive therapies will have a long-term beneficial effect. In addition, in the DIAD study 
patients with type 2 diabetes and no symptoms of CAD were randomly assigned to be screened with 
adenosine-stress radionuclide MPI or not to be screened. In this contemporary study population of 
patients with diabetes, the cardiac event rates were low and were not significantly reduced by MPI 
screening for myocardial ischaemia over 4.8 years (23). Furthermore, the FACTOR-64 study in 
patients with type 1 or type 2 diabetes of at least 3 to 5 years’ duration and without symptoms of 
CAD were included and randomly assigned to CAD screening with CTCA or to standard national 
guidelines-based optimal diabetes care. For this population it was shown that the use of CTCA to 
screen for CAD did not reduce the composite rate of all-cause mortality, nonfatal MI, or unstable 
angina requiring hospitalisation at 4 years (24). Therefore, in patients with a low prior probability of 
CAD, it seems very unlikely that any testing will reduce cardiac events compared to no testing and 
appropriate risk factor modification. Moreover, for patients with stable CAD (excluding left main 
trunk disease and multi-vessel disease in diabetics), there are no randomised trials that support 
revascularisation to reduce hard cardiovascular end-points (cardiovascular death or MI). Therefore, 
unless these patients have limiting angina despite medical therapy, these revascularisations may be 
unnecessary (this is the so-called oculostenotic reflex).  
 
Furthermore, in an analysis of the National Cardiovascular Data Registry (NCDR) in patients 
undergoing elective CAG, it was found that in 70% of the patients undergoing invasive CAG after 
CTCA had obstructive disease, which represents more than 50% improvement in identifying patients 
with obstructive disease compared to any functional test (i.e. xECG, SE, and CMRI) (P <.001) (25). 
Based on these results the PROMISE trial (26) was undertaken, in order to provide a snapshot of real-
world care for patients with suspicion of CAD. The most remarkable finding in the PROMISE trial was 
the diagnostic performance of CTCA over functional testing to identify obstructive CAD, i.e. 71.2% of 







patients undergoing invasive CAG after CTCA had obstructive disease compared to only 47.5% of 
functional test group patients (27). These numbers are remarkably similar to the NCDR data. This is 
crucial information as we attempt to properly stratify chest pain patients based on symptoms, with 
revascularisation and proper diagnosis of angina hanging in the balance (25). Couched in those 
terms, the sensitivity and specificity of non-invasive tests, particularly the functional ones which do 
not demonstrate stenosis directly, in relation to an angiographic standard may not be the best 
outcome parameter to use in economic modelling. Furthermore, although the results of PROMISE 
demonstrated better diagnostic accuracy of CTCA, it also demonstrated an obvious advantage of an 
anatomic approach, allowing more preventive therapies to be applied. Yet, in stable chest pain, there 
is no improvement in outcomes in the first year of statin or aspirin use, but as time progresses, the 
event curves in multiple studies diverge. This was impressively demonstrated in a second large scale 
study published simultaneously to PROMISE called SCOT-HEART assessing CTCA in patients with 
suspected angina due to CAD (28). In SCOT-HEART patients with suspected CAD were randomised to 
receive either only standard workup (in most cases, functional testing) or standard workup plus 
CTCA. In this trial, CTCA reclassified the diagnosis of CAD in 27% of the patients, and the diagnosis of 
angina due to CAD in 23% of patients (standard of care respectively 1% and 1%; P<.0001). This 
changed planned investigations (15% vs. 1%, P<.0001) and treatments (23% vs. 5%, P<.0001). Three 
year follow-up in SCOT-HEART demonstrated that the cardiovascular event rate was reduced by 50% 
in the CTCA group (28).  
Furthermore, analyses were performed for several different countries including USA, UK, Australia 
and countries in Europe and Asia. Health care costs vary considerably across countries. In addition, 
and the threshold willingness-to-pay ranged from £10.000-€80.000/QALY. In this respect we 
recognise that diagnostic strategies and treatment decisions may also vary across countries. 
Significant variations in diagnostic strategies between European and the United States are well 
documented and may be related to differences in health care systems, access to testing technologies, 
and risk tolerance (29-31). Furthermore, a wide range of different combinations of imaging strategies 







were compared, and only one study compared arguably all possible imaging modalities. Direct clinical 
comparisons of the outcomes of different strategies are commonly limited to 2 or 3 alternatives, 
whereas decision modelling studies have been able to assess larger number of choices. Only a few 
studies considered a ‘no testing’ strategy, which reflects the natural history of the included patient 
population and associated costs. In addition, the quoted costs of the different tests vary widely 
between the studies included in this systematic review, depending on the assumptions on patient 
volume (for modalities where fixed hardware costs are high) and whether bottom-up costs or prices 
have been used. This has a big impact on the relative cost-effectiveness of tests whose diagnostic 
performances are relatively similar. For example, the differences between the findings of the study of 
Stacul et al. (32) and Dewey et al. (33) considering CTCA can be explained by such factors.  Also the 
supposed superiority of SE over SPECT or CMRI can be explained by such factors, as for example 
shown in the study by Marwick et al. (18) and Tan et al. (34). In addition, Hunink et al.(35) used a 
decision model to determine parameters that would indicate a new non-invasive test could be cost-
effective compared with SE or SPECT, and suggested the costs would have to be lower than $1,000 
with sensitivity and specificity of 95% or more. Further, the recently published SPARC registry study 
in JACC by the group of DiCarli et al. (36) showed that at 2-years the mean costs for patients 
undergoing SPECT as the first-line investigation compared with CTCA or PET as the first-line 
investigation were significantly lower, and patients who underwent CTCA and PET experienced 
significantly higher 90-day rates of downstream CAG (16% and 15%, respectively) as compared with 
patients who underwent SPECT (7%) and new prescriptions for aspirins and statins.  
The higher rate of downstream CAG after CTCA has been documented in some of the included 
studies (37), but not in others (38), (39), (40), (41). The use of invasive procedures varied with: a) the 
degree of abnormality seen on the CTCA, with very few cardiac catheterisations done in patients with 
normal or near-normal CTCA findings, but with a higher rate of catheterisation among patients with 
an abnormal CTCA (42). This observation suggests that the differences in the composition of the 
patient population and in the prevalence of underlying CAD may explain differences between prior 







studies in subsequent use of invasive CAG testing after CTCA. Studies that enrolled younger and 
lower-risk populations (40) should have more frequently normal CTCA findings, and, consequently, 
fewer invasive tests than studies with patient populations that are older, have a higher risk, or both 
(36). Furthermore, the findings of the SPARC registry in favour of SPECT, are in line with findings in 
some of the included studies. A decision model by Garber et al. (41) showed SPECT to be more cost-
effective than PET for non-invasive diagnosis of CAD, and SPECT to be a better option than 
immediate CAG. It should, however, be noted that in their study CTCA was not evaluated, since this 
had not yet been developed. A similar included decision model by Kuntz et al. (43) found SE and 
SPECT to be reasonable initial choices for patients with intermediate probability of CAD, but invasive 
CAG to be optimal for patients with high prior probability of CAD. It should, however, be noted that 
their study did not evaluate PET or CTCA. The decision model of Hernández et al. (44) suggested that 
SPECT was cost-effective compared with xECG or invasive CAG without non-invasive testing. One 
needs to be mindful that this study did not consider CTCA or PET as alternatives. Min et al. (7) used a 
decision model to assess five different strategies using CTCA or SPECT, and projected that strategies 
based on CTCA might be more cost-effective than SPECT-based strategies. In terms of outcomes, 
Shaw et al. (45) (END study) found that patients who underwent initial SPECT with selective cardiac 
catheterisation had lower costs than patients who underwent routine coronary angiography. In the 
EMPIRE study by Underwood et al. (46) it was demonstrated that strategies using MPI were cheaper 
and equally effective when compared with strategies that did not use MPI, both for the cost of 
diagnosis and for overall 2-year management costs; the 2-year patient outcome was the same. 
Sharples et al. (47) randomised 898 patients to SPECT, SE, CMRI, or direct CAG, and found SPECT to 
be as useful as immediate CAG with similar costs. At last, it is not necessarily clear in the current 
iteration that NICE guidance recommends risk assessment to direct choice of investigation of patients 
with stable chest pain and advocates CTCA at any rate rather than functional testing. Yet, many 
people in the low to intermediate probability group of having obstructive CAG will not have a calcium 







score of zero and will therefore go to CTCA directly, but when the prior probability is high enough 
they will go directly to CAG (12). 
Furthermore, the prior probability of CAD differed widely across studies ranging from 1%-90%. Yet, 
research has shown that clinical estimates of prior probability are grossly overinflated in real world 
application. For example, in the CONFIRM CT registry, the actual prevalence of obstructive CAD in 
patients with typical or atypical angina across the range of prior probabilities was only 20-50% of that 
predicted by the traditional Pryor approach (48). Irrespective of age, sex, risk factors and the 
typicality of angina, no patient group had an observed prevalence of obstructive CAD >60%. Other 
studies have also shown that most patients who undergo invasive CAG after ischaemia testing have 
non-obstructive or normal arteries (49). Therefore, in real life, the group of patients for whom direct 
CAG is cost-effective compared with CTCA may actually not exist. Interestingly, as in the case of the 
main population of the EVINCI study, traditional criteria for calculating prior probability 
overestimated the prevalence of haemodynamically significant CAD by 37% (50).  
Limitations of this study 
Our study has several limitations. First, although we carefully developed a search strategy, the search 
strategy could have missed possible relevant articles. Second, the review is based solely on published 
papers, and is thus restricted to the level of detail reported in the original papers. Third, studies 
evaluating CTCA based strategies were overrepresented in this systematic review. Studies evaluating 
a strategy of no testing were underrepresented. In addition, even though xECG and PET were 
included in some studies, these testing strategies have also been underrepresented. This may have 
biased the results presented in this systematic review. Fourth, most diagnostic accuracy studies 
suffer from referral bias. This may have distorted the diagnostic test characteristics used in the 
published cost-effectiveness analyses, which in turn diminishes the comparability and generalisability 
of the included cost-effectiveness studies. Further, all studies except three used CAG alone as the 
reference standard, whereas over the past years, CAG is increasingly used in combination with 







functional testing using catheter-based FFR for determining significance of stenosis. Finally, this 
systematic review is based on cost-effectiveness literature about stable chest pain patients, and the 
results should not be extrapolated to other settings, such as the diagnostic evaluation of patients 
presenting with acute chest pain.  
Implications for clinical practice 
The results of this systematic review suggest that for patients with a low to intermediate prior 
probability of having significant CAD, the optimal (sequence of) diagnostic imaging tests remains 
uncertain.  
Although CTCA is gaining acceptance as a tool in the initial diagnostic approach of patients with low 
to intermediate prior probability of CAD, it is unlikely that the test will completely replace functional 
or invasive testing since this is still commonly used in patients presenting with a prior probability 
≥50%. Furthermore, CTCA and CAG assess anatomic CAD stenosis, but do not assess the functional 
significance of coronary lesions. As a result, there is a potential for stenoses seen on CTCA and CAG 
that are not flow limiting, and therefore may require further evaluation with functional testing. 
Functional testing should therefore be regarded as incremental to anatomical imaging in order to 
determine the clinical significance of stenosis, and the potential benefit of revascularisation and 
prognosis. Functional testing may be performed using xECG, SE, SPECT, PET, CMRI, CTCA-based FRR 
estimation or catheter-based invasive FFR measurement, the latter being the current reference 
standard test. In the future CTCA may allow the assessment of ischaemia using perfusion techniques 
or virtual FFR measurement, however, these are not yet established procedures. The role of 
functional testing for less severe stenoses is unclear: in such cases, the results of functional tests may 
guide the intensity of medical therapy, lifestyle interventions and the frequency of follow up visits. In 
this respect, more randomised clinical trials and cost-effectiveness research is needed. 
 
 







In line with a previously performed systematic overview (51), the current systematic review 
highlights the importance of risk stratification based on prior probability to guide imaging decisions. 
Ideally, the prior probability is estimated using a risk calculator that incorporates patient 
characteristics, medical history, risk factors and previous diagnostic test findings (11). At each stage 
of the diagnostic workup process, new findings are included in the calculator in order to revise the 
probability which is then used to make the next workup decision. This leads to an individualised and 
integrated approach, consistent with the current focus on personalised medicine. 
Conclusions 
In conclusion, the results from this study suggest that CTCA as an initial gatekeeper imaging test is 
cost-effective under varying assumptions in patients presenting with stable chest pain with a low to 
intermediate prior probability of CAD. Yet, as seen in the SPARC registry and the PROMISE trial, the 
limitations of anatomical imaging raise concern that an over-reliance on coronary anatomy may 
result in excessive invasive CAGs and that the ‘oculostenotic reflex’ will increase revascularisation 
procedures. In addition, as has been seen in recent clinical trials (COURAGE, DIAD, FACTOR-64, 
FAME2, PROMISE), cardiac event rates with optimal medical therapy, even in patients with 
established CAD, are quite low. Therefore, in low risk patients with suspected CAD, it seems very 
unlikely that any testing will reduce cardiac events when compared to no testing and appropriate risk 
factor modification. Thus, no testing is likely more cost-effective than any imaging strategy in low risk 
patients. However, a strategy of no testing was underrepresented in the included studies. Therefore, 
in order to be able to firmly conclude that CTCA is the preferred strategy in low risk patients, a 
randomised trial (with economic sub-studies) comparing CTCA to a no testing strategy in low risk 
patients would be helpful. Further, the results from this study suggest SE or SPECT to be cost-
effective strategies if functional testing is required in patients presenting with stable chest pain with 
an intermediate prior probability of CAD. However, PET scanning and xECG have not been studied as 
intensely as other non-invasive functional testing strategies, and should therefore also be evaluated 
carefully in larger studies to assess its impact on clinical and economical outcomes. For patients 







presenting with stable chest pain with a high prior probability the results from this study suggest 
direct CAG to be the most cost-effective initial strategy. Yet, studies have shown that clinical 
estimates of prior probability are grossly overinflated in real world application. Therefore, in real life, 
the group of patients for whom direct CAG is cost-effective compared with CTCA may not actually 
exist. For this reason, although this study provides a summary of published economic evaluations in 
the form of a quick reference and allows for easy comparison, the results should be seen as a spur to 
further research rather than as providing definitive conclusions. Further studies are needed to 
compare the cost-effectiveness of alternative non-invasive testing approaches, including a no-testing 
strategy, for patients with stable chest pain symptoms suggestive of CAD.  
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Figure 1: Literature search and selection numbers of articles with respect to economic 












Figure 2: Quality assessment of the included economic evaluations and decision models using the modified CHEERS checklist 
 Study 
 
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14 Item 15 Item 16 Item 17 Item 18 
Amemiya (52)  + + + + + + + + + + - + + + + - ± - 
Genders  (5) + + + + + + + + + + + + + + + + + + 
Kreisz (53) + + + + + + + + + + + ± - + + + + ± 
Ladapo (6) + ± + + + + + ± + + + + ± + + + ± ± 
Min (7) ± ± + + + + + + + + + + + + + + ± - 
Genders (54) + + + + + + + ± + + + + + + + + + + 
Boldt (55) + + + + + + + + + + - ± + + + + ± ± 
Iwata (56) + + + + + + + ± + + - + + ± + + ± ± 
Catalan (57) ± + + + + + + + + + - + + ± + + + - 
Walker (58) + + + + + + + + + + ± + + + ± + + - 
Halpern (59) + + + + + + + ± ± + - + + + + + + ± 
Kim (60) ± + + + + + + + + + - + + + + + + ± 
Demir (61) + + + ± + + ± NA + + - ± + + NA NA ± - 
Min  (62) + + + ± + + + + + + ± ± + + + + + ± 
Patel (63) + + + ± + ± ± NA + + - ± + + + + ± - 
Raggi (64) + + + + + + + NA + ± - + + + + + + - 
Halpern (65) + + + + + + + ± ± + - + + + + + + ± 
Garber (41) + + + + + + + + + + + + + + + + + ± 
Genders (17) + + + + + + + + + + + + + + + + + + 
Kuntz (43) + + + + + + + + + + + + + + + + + + 







Ferreira (19) + + + + + + + ± + ± - ± + + + + ± ± 
Laufer (66) + ± + + + ± ± NA + ± - ± + + NA NA ± ± 
Thom (67) + + + + + + + + + + + ± + + + + + + 
Rogers (12) + + + ± ± + + NA ± + - ± + + NA NA ± - 
Kimura (68) + + + + ± + + + + ± - ± + + NA NA + + 
Hachamovitch (69) + - + + + + + + - ± - ± + + + + ± + 
Patterson (16) + + + + + + + + + ± - + + + + + + ± 
Shaw (70) + + + + + + + + + ± + ± + + NA NA + ± 













Study Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14 Item 15 Item 16 Item 17 Item 18 
Petrov (72) + + + + + + + ± + ± - ± + + NA NA ± ± 
Nielsen (39) + + + + + + + ± + + - ± + + NA NA + ± 
Shaw (73) + + + + + + + + ± + + ± + + + + + ± 
Marwick (18) + + + + + + + + + + + ± ± + NA NA + + 
Underwood (46) + + + + ± ± + + ± + - ± ± + NA NA ± + 
Wennike (74) + + + + + + + NA ± + - - ± + NA NA ± - 
Darlington (75) + + + + ± ± + ± + + - + + + + + ± ± 
Meyer (76) + + + + + + + + + + - + + + + + + - 
Tan (34) + + + + ± + ± NA + + - + + + + + + + 
Dewey (33) + + + + + + + ± + + + + + + + + + ± 
Raman (77) + + + + + + ± + + + - + + + + + + + 
Hlatky (9) + + + + + + + + + + - + + + + + + + 
Hlatky (36) + + + + + + + + + + - + + + + + + + 
Zacharias (78) + - + + + ± + + + ± - ± + + NA NA ± ± 
Muzzarelli (79) + + + + ± ± + NA + ± - ± + + + + ± ± 
Pilz (80) ± + + + ± ± - NA ± + - ± + + + + - + 
Marwick (81) + + + + ± ± + + ± ± - ± + + NA NA ± + 
Lorenzoni (82) + + + + + ± + + ± + + ± + + + + ± + 
Tardif (83) + + + + + + + ± ± + - + + + + + + ± 
Cheng (84) + + + + + ± + ± ± + + + + + + + ± + 
Cole (85) + + + + + ± + NA ± ± - ± ± + + + ± + 







Lee (86) + + + + + + ± + + ± - + + + + + + + 
Min (87) + + + + + + + + + ± - + + + NA NA + + 
Moschetti (88) + + + + + ± + NA + + - ± + ± NA NA + + 
Moschetti (89) + + + + + + + + ± ± + ± + ± + + + + 
Min (90) + + + ± + ± + + ± + - ± + + + + ± + 
Mattera (91) + + + + + ± + ± ± + - ± + + NA NA ± + 
Sabharwal (92) + + + + + ± ± ± + ± - + + + + + ± + 
Shaw  (93) + + + + + ± + + + + ± ± + + + + + + 
Lee  (94) + + + + + ± ± - + ± + ± + + + + ± - 
Merhige (95) + + + + + ± + + ± ± - ± + + NA NA ± - 
Rumberger (96) + + + + + + + + ± ± - + + + + + + ± 










Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14 Item 15 Item 16 Item 17 Item 18 
Shaw  (45) + + + + + ± + + + + + ± + + + + + + 
Shreibati (37) + + + + + + + ± ± ± - ± + + + + ± + 
Cheezum (40) + + + + + ± + + ± ± - + + + NA NA + ± 
Hernández (44) + - + + + + + + + + + + + + + + + + 
Menon (97) + + + + + ± + ± ± ± - ± + + NA NA ± ± 
Chamuleau (98) + + + + + + + + + + - + + + + + + ± 
Stacul (32) + + + + ± ± ± + + ± - ± ± + NA NA ± ± 
Min (38) + + + + + + + ± ± + - + + + + + + + 




Figure 2: Quality assessment of the included economic evaluations and decision models using the modified CHEERS checklist 
Reviewers judgments of the quality of included economic evaluations and decision models, according to a modified version of the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) checklist.  
yes (green/+ ) indicates high quality or low risk of bias, no (red/-)  indicates poor quality or high risk of bias, moderate (orange/±) indicates moderate 
quality or moderate risk of bias. NA (white) indicates not appropriate/not applicable.   







Table 1: Type of sensitivity analysis performed and most important  factors influencing the optimal 
choice of imaging algorithm 
Type of Sensitivity 
analysis  
Most important influencing factors  Reference 
One-way only  
Threshold for PCI ≥70% vs ≥50% stenosis Hlatky (71) 
Sensitivity to detect severe CAD, Willingness-to-pay 
threshold 
Garber (41) 
Patient managed by interventional cardiologist vs. non-
invasive cardiologist 
Thom (67) 
Prognosis in patients with FN test results, Nondiagnostic 
test rate 
Lee (94) 
Prior probability of CAD, Test performance, Costs of CAG Dewey (33) 
Prior probability of CAD, Willingness -to- pay for an 
additional correct diagnosis 
Ferreira (19) 
Prior probability of CAD, Test performance Dorenkamp (99) 
Prior probability of CAD, Sensitivity of SE Kim (60) 
Prior probability of CAD, Sensitivity of CMRI, Rate of 
complications in false-negatives 
Moschetti (89) 
Prior probability of CAD, Positivity criterion for CACS Rumberger (96) 
Prior probability of CAD, (risks of) Radiation exposure in 
women 
Ladapo (6) 
Prior probability of CAD, Test performance, Effective 
radiation dose 
Halpern (59) 
Prior probability of CAD Raman (77), Boldt (55), Pilz (80), Lee (86), Shaw 
(73) 
Prevalence of obstructive CAD, Costs of CTCA and CAG Cole (85) 
Prevalence of CAD Halpern (65), Patel (63) 
No variables that changed the decision  Shreibati  (37), Lorenzoni (82), Shaw (45), 
Patterson (16) 
Cost data used microcosting analysis vs. reimbursement 
fees, Treatment time, Overhead costs 
Tan (34) 
Costs of CTCA, Costs of CAG, Team experience with CTCA Catalán (57) 
Costs of CMRI Iwata (56) 
Costs of FFRct Hlatky (9) 







Costs of diagnostic tests, Hospitalization, and 
Medications 
Tardif (83) 
CACS cut-point Raggi (64) 
One-way and Two-way Unit costs of CAG, Sensitivity of CTCA Cheng (84) 
One-way and 
Bootstrapping 
No variables that changed the decision  Hlatky (36) 
One-way, Two-way, 
and Multi-way  
Costs of CTCA Kreisz (53) 
One-way and 
Probabilistic  
Test performance, Costs of dual energy CT vs. SPECT Meyer (76) 
Prior probability of CAD, Test performance, Willingness-
to-pay threshold 
Hernández (44) 
Probability of CAD, Consequence of a false-positive result Genders (17) 
Prior probability of CAD, Sensitivity of CTCA Amemiya (52) 
Prior probability of CAD, CCS grade, Re-identification rate 
of FN, Costs of CMRI (relative to SPECT)  
Walker (58) 




and Probabilistic   
Optimization criterion (i.e. outcome of interest), Prior 
probability of CAD, Sensitivity/specificity of CTCA 
Genders (5) 
Nature and severity of chest pain, Prevalence of CAD, 
Willingness-to-pay threshold 
Kuntz (43) 
Probabilistic only  
Prior probability of CAD in men Genders (54) 




sensitivity analysis and 
Cox proportional 
hazards model 




Sample vs. Entire patient population  Min  (38) 
Subgroup analysis 
Prior probability  Sabharwal (92), Hachamovitch (69) 
Known vs. suspected CAD Muzzarelli (79) 
Bootstrapping  No variables that changed the decision  Darlington (75), Min (90), Min (62) 
Not performed Not applicable  Stacul (32),Moschetti (88), Petrov (72), Min (87), 














Marwick (18), Wennike (74), Laufer (66), Merhige 
(95), Underwood (46), Shaw (70), Nielsen (39), 
CHeezum (40), Menon (97),  Marwick (81), 
Mattera (91), Zacharias (78), Kimura (68), Rogers 
(12), Demir (61) 







Table 2: Non-invasive imaging tests and imaging algorithms1 analysed  
CTCA-based 
strategies  
Reference MPS-based strategies  Reference  xECG-based 
strategies 
Reference 
ms CTCA±CAG Dewey (33) Nuclear perfusion imaging  Tardif (83) xECG Shreibati (37), Shaw (70), Nielsen (39), 
Hachamovitch (69), Marwick (81) 
eb CTCA±CAG Dewey (33) SPECT±CAG Genders (17), Raman (77), Rumberger (96), 
Walker (58), Iwata (56), Boldt (55), Ladapo (6), 
Min (7), Lee (86), Kuntz (43), Thom (67),  Merhige 
(95), Sabharwal (92), Patterson (16), Shaw (73), 
Muzzarelli  (79), Garber (41), Tan (34), 
Hernández (44), Hlatky (36), Meyer (76), Shaw 
(45) 
xECG±CTCA±CAG Ladapo (6), Ferreira (19), Halpern (59) 
md CTCA Min (90), Min (38) SPECT±CTCA±CAG Min (7) xECG±MPS±CAG Ferreira (19), Underwood (46), Raggi (64) 
64s-CTCA±CAG Kreisz (53), Catalán (57) MPS±CAG Shaw (93), Ferreira (19), Underwood (46), 
Halpern (59), Demir (61) 
xECG±CAG Raman (77), Rumberger (96), Walker 
(58), Ladapo (6), Dewey (33), Kuntz (43), 
Marwick (18),  Lorenzoni (82), Sabharwal 
(92), Kim (60), Underwood (46), 
Patterson (16), Muzzarelli (79), Garber 
(41), Tan (34), Hernández (44), Halpern 
(59), Marwick (81) 
64s-CTCA Stacul (32) MPS±CTCA±CAG Halpern (59) xECG±SE±CAG Lorenzoni (82), Tan (34), Zacharias (78), 
                                                            
1 See footnotes Table 2. PTCA percutaneous transluminal coronary angioplasty; ph  pharmacologic; ms  multislice; eb  electron-beam; md multidetector; ct computed tomography 








ds CTCA±CAG Dorenkamp (99) SPECT±PTCA Chamuleau (98) xECG±CMRI±CAG Walker (58) 
CTCA Genders (17), Min (87), Shreibati 
(37), Min (62), Nielsen (39), 
Cheezum (40), Darlington (75)2 
SPECT±FFR±PTCA Chamuleau (98) xECG±SPECT±CAG Raman (77), Walker (58), Genders (54), 
Muzarelli (79), Tan (34), Hernández (44) 
CTCA±CAG Genders (17), Genders (5), Ladapo 
(6), Amemiya (52), Min (7), Halpern 
(65), Lee (86), Ferreira (19), Patel 
(63), Hlatky (71), Menon (97), Cole 
(85), Cheng (84), Hlatky (36), 
Halpern (59), Kimura (68), Rogers 
(12), Demir (61) 
Planar thallium imaging±CAG Garber (41) xECG±MPS Mattera (91) 
CTCA±xECG±CAG Ladapo (6), Halpern (59) ph SPECT±CAG Lee (94) xECG±SE±SPECT±CAG Tan (34) 
CTCA±SE Genders (17), Rogers (12) PET±CAG Merhige (95), Patterson (16), Garber (41), Hlatky 
(36) 
    
CTCA±SE±CAG Genders (17), Halpern (59) SPECT Genders (17), Min (87), Min (62), Min (38), 




CTCA±SPECT Genders (17) Dual  energy CT MPI±CAG Meyer (76) ETT±CAG Rogers (12), Demir (61) 
CTCA±SPECT±CAG Genders (17), Min (7) MPS Min (90), Shreibati (37), Shaw (70), Cheezum 
(40), Mattera (91) 
ETT±SE±CAG Rogers (12) 
CTCA±MPS±CAG Halpern (59) x-thallium SPECT±CAG                  Laufer (66), Kim (60) ETT±CACS±CAG Demir (61) 
                                                            
2 Triage strategy: neither CTCA nor CAG in the low-risk group, CTCA triage in the intermediate-risk group and CAG in the high-risk group (based on the Duke Clinical Score) 







CTCA±CMRI Genders (17) ETT±CTCA±CAG Demir (61) 




ETT±ph SE±CAG Demir (61) 
CTCA±CAG±FFRcag Hlatky (71) ETT±MPS±CAG Demir (61) 






Reference CACS-based strategies  Reference  CMRI-based 
strategies  
Reference 
Contrast SE Tardif (83) CACS±CAG Raman (77), Rumberger (96), 
Demir (61) 
CMRI Genders (17) 
SE Genders (17), Shreibati (37), Zacharias (78), Marwick(81) CACS±CTCA±CAG Genders (54), Ferreira (19) CMRI±CAG Genders (17), Walker (58), Iwata (56), 
Boldt (55), Pilz (80), Petrov (72), Dewey 
(33), Thom (67) 
SE±CAG Genders (17), Rumberger (96), Ladapo (6), Dewey (33), 
Ferreira (19), Kuntz (43), Marwick (18), Halpern (59), 
Lorenzoni (82), Laufer (66), Thom (67), Kim (60), Shaw 
(73), Garber (41), Tan (34), Wennike  (74), Marwick (81), 
Zacharias (78) 
CACS+SPECT±CAG Raman (77) CMRI+SE/CTCA/SPECT Moschetti (88) 
ph SE±CAG Lee (94), Demir (61) CACS±xECG±CAG Raggi (64) CMRI+CAG and FFR Moschetti (89) 
exercise 
SE±CAG 
Lee (94) CACS±xECG±MPI±CAG Raggi (64)  







SE±SPECT±CAG Tan (34) CACS±CTCA Rogers (12) 
SE±CTCA± CAG Halpern (59)   
 
CAG/FFR Reference  No testing  Reference 
CAG Genders (17), Kreisz (53), Stacul (32), Catalán (57), Shaw (93), Raman (77), Rumberger (96), 
Walker (58), Boldt (55), Pilz (80), Petrov (72), Genders (5), Ladapo (6), Amemiya (52), 
Moschetti (88), Min (7), Halpern (65), Dorenkamp (99), Dewey (33), Ferreira (19), Kuntz (43), 
Thom (67), Shaw (93), Kim (60), Underwood (46), Patterson (16), Patel (63), Menon (97), 
Garber (41), Tan (34), Hernández (44), Cole (85), Cheng (84), Wennike (74), Hlatky (9),  
Hlatky (71), Zacharias (78), Halpern (59), Tan (68), Demir (61), Darlington (75),  Shaw (45), 
Marwick (81) 
No testing          
 
 Genders (17), Ladapo (6), Amemiya 
(52), Ferreira (19), Kuntz (43), Kim 
(60), Meyer (76), Wennike (74), 
Halpern (59), Zacharias (78) 
  
CAG±FFRcag Moschetti (89), Halpern (71), Kimura (68) 
FFR±PTCA Chamuleau (98) 
FFRct  Hlatky (9) 
See footnotes: Table 5 
 
 





























Caption Table 3 
*** Only studies reporting the comparative cost-effectiveness of different imaging strategies for patients with stable chest pain at different prior probabilities of CAD.   
^ Only MPI when abnormal xECG 
√* Imaging strategy ±CAG 
√` FFR if CMRI intermediate, CAG if CMRI positive  
* All tests performed as outpatient tests 
** CAG performed as inpatient test 
 
¶ Compared only functional testing 
ǂ Compared only anatomical testing 
¶ + ǂ Compared both functional and anatomical testing  
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